scholarly journals Multimodal trips, quality of life and wellbeing: An exploratory analysis

2022 ◽  
Vol 24 ◽  
pp. 101330
Author(s):  
Alec Cobbold ◽  
Christopher Standen ◽  
Leah Shepherd ◽  
Stephen Greaves ◽  
Melanie Crane
Religions ◽  
2015 ◽  
Vol 6 (4) ◽  
pp. 1249-1262 ◽  
Author(s):  
Waraporn Saisunantararom ◽  
Areewan Cheawchanwattana ◽  
Talerngsak Kanjanabuch ◽  
Maliwan Buranapatana ◽  
Kornkaew Chanthapasa

2019 ◽  
Vol 49 ◽  
pp. 10-17 ◽  
Author(s):  
Monique M. Ridosh ◽  
Kathleen J. Sawin ◽  
Gayle Roux ◽  
Timothy J. Brei

2012 ◽  
Vol 30 (15_suppl) ◽  
pp. 598-598 ◽  
Author(s):  
Javier Cortes ◽  
José Baselga ◽  
Young-Hyuck Im ◽  
Graham Ross ◽  
Emma Clark ◽  
...  

598^ Background: CLEOPATRA compared the efficacy and safety of the HER2 dimerization inhibitor pertuzumab (P) plus trastuzumab (T) and docetaxel (D) with placebo (Pla)+T+D in HER2-positive 1st-line MBC. Pts in both arms received a median of 8 cycles of D; Pla/P+T was continued until progressive disease (PD). The safety profile in both arms was similar with a substantial decrease in adverse events (AEs) once chemotherapy finished. The independently assessed progression-free survival was significantly improved with P+T+D compared with Pla+T+D; objective response and duration of response were also improved with P+T+D (Baselga NEJM 2012). Here we report health-related quality of life (HRQoL) data from CLEOPATRA. Methods: Time to deterioration of HRQoL was evaluated using the FACT-B questionnaire and defined as decrease from baseline (BL) of ≥5 points in the TOI-PFB subscale score. Female pts completed questionnaires every 3rd cycle of therapy within 3 days before each tumor assessment until independently determined PD. An exploratory analysis investigated time to deterioration in breast cancer symptoms and functions. Results: 56.7% (Pla+T+D) and 59.5% (P+T+D) of pts experienced deterioration of HRQoL during the study based on TOI-PFB. The median time to deterioration was 18.3 vs 18.4 wks (~6 cycles) (HR 0.97; P = .7161). At Cycle 6, the mean reduction in TOI-PFB score from BL was –3.5 (Pla+T+D) vs –3.0 (P+T+D). At subsequent cycles, when most pts had discontinued D, mean reductions were smaller, suggesting that after an early decline patients’ scores improved slightly. Overall, mean changes were small in both arms. Compliance with completion of the FACT-B questionnaire was ≥75% beyond the 1st year in both arms. An exploratory analysis suggested that time to deterioration in BCS score, which measures symptoms and issues relevant in breast cancer, was delayed with P+T+D (18.3 vs 26.7 wks; HR 0.77; P = .0061). Conclusions: Combining P with T+D appears to have no detrimental effect on HRQoL. Results suggest that P+T+D is associated with a substantial delay in the time to deterioration in BCS score as would be expected given the improved efficacy and the low incidence of AEs once D is discontinued.


2008 ◽  
Vol 180 (6) ◽  
pp. 2409-2414 ◽  
Author(s):  
Wesley M. White ◽  
Natalia Sadetsky ◽  
W. Bedford Waters ◽  
Peter R. Carroll ◽  
Mark S. Litwin

Sign in / Sign up

Export Citation Format

Share Document